Weight-loss and diabetes drugs are heavy in demand and huge in the news. While media craze is never an innovation indicator for us, the Singularity Think Tank confirms the unique blockbuster status and innovative nature of GLP1-receptor-agonists. Learn more about why our experts see continued evidence of market growth opportunities and further therapeutic advancements for these drugs in the video below.